{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T03:42:42Z","timestamp":1785382962064,"version":"3.55.0"},"reference-count":161,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000165","name":"Sick Kids Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003579","name":"University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022082","name":"Garry Hurvitz Centre for Brain and Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022082","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008453","name":"Ontario Institute for Regenerative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015452","name":"Canadian Society of Nephrology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015452","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012280","name":"Rare Disease Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012280","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.neurot.2025.e00631","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T07:58:33Z","timestamp":1751011113000},"page":"e00631","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pediatric multiple sclerosis: Improving outcome through high-efficacy therapies"],"prefix":"10.1016","volume":"22","author":[{"given":"Lama Saleh","family":"Aljomah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Ann","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2025.e00631_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.yapd.2019.03.003","article-title":"Pediatric multiple sclerosis","volume":"66","author":"Langille","year":"2019","journal-title":"Adv Pediatr"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00631_bib2","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1177\/0883073812456084","article-title":"Pathogenesis of pediatric multiple sclerosis","volume":"27","author":"Vargas-Lowy","year":"2012","journal-title":"J Child Neurol"},{"issue":"25","key":"10.1016\/j.neurot.2025.e00631_bib3","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa067597","article-title":"Natural history of multiple sclerosis with childhood onset","volume":"356","author":"Renoux","year":"2007","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00631_bib4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1055\/s-0037-1604421","article-title":"Diagnostic challenges in pediatric multiple sclerosis and neuromyelitis optica spectrum disorder","volume":"16","author":"Yeshokumar","year":"2018","journal-title":"J Pediatr Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00631_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12883-018-1026-3","article-title":"Pediatric multiple sclerosis: a review","volume":"18","author":"Alroughani","year":"2018","journal-title":"BMC Neurol"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00631_bib6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/children6060075","article-title":"Differential diagnosis of pediatric multiple sclerosis","volume":"6","author":"Galardi","year":"2019","journal-title":"Children"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00631_bib7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/ene.12327","article-title":"Clinical presentation of pediatric multiple sclerosis before puberty","volume":"21","author":"Huppke","year":"2014","journal-title":"Eur J Neurol"},{"issue":"S4","key":"10.1016\/j.neurot.2025.e00631_bib8","doi-asserted-by":"crossref","first-page":"s326","DOI":"10.1007\/s10072-004-0335-z","article-title":"Multiple sclerosis in children under 10 years of age","volume":"25","author":"Ruggieri","year":"2004","journal-title":"Neurol Sci"},{"key":"10.1016\/j.neurot.2025.e00631_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102260","article-title":"Epidemiology of pediatric multiple sclerosis: a systematic literature review and meta-analysis","volume":"44","author":"Yan","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00631_bib10","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1177\/13524585231185046","article-title":"Social determinants of health and disparate disability accumulation in a cohort of Black, Hispanic, and White patients with multiple sclerosis","volume":"29","author":"Orlando","year":"2023","journal-title":"Mult Scler"},{"issue":"19","key":"10.1016\/j.neurot.2025.e00631_bib11","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1212\/WNL.0b013e3182918cc2","article-title":"Incidence of multiple sclerosis in multiple racial and ethnic groups","volume":"80","author":"Langer-Gould","year":"2013","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00631_bib12","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1177\/1352458508101933","article-title":"Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States","volume":"15","author":"Chitnis","year":"2009","journal-title":"Multiple Sclerosis Journal"},{"issue":"14","key":"10.1016\/j.neurot.2025.e00631_bib13","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00631_bib14","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00631_bib15","first-page":"246","article-title":"Optic neuritis as first clinical manifestations the multiple sclerosis","volume":"26","author":"Halilovic","year":"2014","journal-title":"Mater Sociomed"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00631_bib16","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nrneurol.2009.158","article-title":"Pediatric multiple sclerosis","volume":"5","author":"Yeh","year":"2009","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00631_bib17","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S1474-4422(07)70242-9","article-title":"Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions","volume":"6","author":"Banwell","year":"2007","journal-title":"Lancet Neurol"},{"issue":"9_suppl ment_2","key":"10.1016\/j.neurot.2025.e00631_bib18","article-title":"Pediatric multiple sclerosis","volume":"87","author":"Waldman","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00631_bib19","doi-asserted-by":"crossref","DOI":"10.1001\/archneurol.2008.505","article-title":"Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis","volume":"66","author":"Gorman","year":"2009","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00631_bib20","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.msard.2013.06.004","article-title":"Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years","volume":"3","author":"Benson","year":"2014","journal-title":"Mult Scler Relat Disord"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00631_bib21","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1212\/01.WNL.0000036907.37650.8E","article-title":"Course and prognosis in early-onset MS","volume":"59","author":"Simone","year":"2002","journal-title":"Neurology"},{"issue":"20","key":"10.1016\/j.neurot.2025.e00631_bib22","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000012869","article-title":"Association of age at onset with gray matter volume and white matter microstructural abnormalities in people with multiple sclerosis","volume":"97","author":"Bonacchi","year":"2021","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00631_bib23","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/0883073812464816","article-title":"Cognitive impairment occurs in children and adolescents with multiple sclerosis","volume":"28","author":"Julian","year":"2013","journal-title":"J Child Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00631_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194873","article-title":"Cognitive deficits including executive functioning in relation to clinical parameters in paediatric MS patients","volume":"13","author":"Wuerfel","year":"2018","journal-title":"PLoS One"},{"issue":"9_suppl ment_2","key":"10.1016\/j.neurot.2025.e00631_bib25","article-title":"Pediatric multiple sclerosis","volume":"87","author":"Amato","year":"2016","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00631_bib26","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1177\/0883073812465010","article-title":"Cognitive trajectories in 4 patients with pediatric-onset multiple sclerosis","volume":"28","author":"Marin","year":"2013","journal-title":"J Child Neurol"},{"issue":"20","key":"10.1016\/j.neurot.2025.e00631_bib27","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1212\/01.wnl.0000435551.90824.d0","article-title":"Gray matter damage predicts the accumulation of disability 13 years later in MS","volume":"81","author":"Filippi","year":"2013","journal-title":"Neurology"},{"issue":"20","key":"10.1016\/j.neurot.2025.e00631_bib28","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1212\/01.wnl.0000312276.23177.fa","article-title":"Cognitive and psychosocial features of childhood and juvenile MS","volume":"70","author":"Amato","year":"2008","journal-title":"Neurology"},{"issue":"13","key":"10.1016\/j.neurot.2025.e00631_bib29","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1212\/WNL.0b013e3181f4d821","article-title":"Cognitive and psychosocial features in childhood and juvenile MS","volume":"75","author":"Amato","year":"2010","journal-title":"Neurology"},{"issue":"16","key":"10.1016\/j.neurot.2025.e00631_bib30","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1212\/WNL.0000000000000885","article-title":"Neuropsychological features in childhood and juvenile multiple sclerosis","volume":"83","author":"Amato","year":"2014","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00631_bib31","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1001\/jamaneurol.2019.1546","article-title":"Long-term cognitive outcomes in patients with pediatric-onset vs adult-onset multiple sclerosis","volume":"76","author":"McKay","year":"2019","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00631_bib32","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3390\/biomedicines8040071","article-title":"Current advances in pediatric onset multiple sclerosis","volume":"8","author":"Fisher","year":"2020","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00631_bib33","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1177\/0883073812450750","article-title":"Fatigue and depression in children with demyelinating disorders","volume":"28","author":"Parrish","year":"2013","journal-title":"J Child Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00631_bib34","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1186\/s12883-021-02396-1","article-title":"Prevalence and burden of multiple sclerosis-related fatigue: a systematic literature review","volume":"21","author":"Oliva Ramirez","year":"2021","journal-title":"BMC Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00631_bib35","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/dmcn.13055","article-title":"Fatigue in childhood multiple sclerosis","volume":"58","author":"Yeh","year":"2016","journal-title":"Dev Med Child Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00631_bib36","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/1352458511420846","article-title":"Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis","volume":"18","author":"Goretti","year":"2012","journal-title":"Multiple Sclerosis Journal"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00631_bib37","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1177\/1352458509345902","article-title":"Fatigue and quality of life in pediatric multiple sclerosis","volume":"15","author":"MacAllister","year":"2009","journal-title":"Multiple Sclerosis Journal"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00631_bib38","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.pediatrneurol.2010.03.007","article-title":"Health-related quality of life is reduced in pediatric multiple sclerosis","volume":"43","author":"Mowry","year":"2010","journal-title":"Pediatr Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00631_bib39","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S2352-4642(18)30026-9","article-title":"MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study","volume":"2","author":"Fadda","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00631_bib40","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/dmcn.15098","article-title":"Incidence of paediatric multiple sclerosis and other acquired demyelinating syndromes: 10-year follow-up surveillance study","volume":"64","author":"Abdel-Mannan","year":"2022","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.neurot.2025.e00631_bib41","article-title":"Revisions of the McDonald criteria","volume":"vol 2024","author":"Montblan","year":"2024"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00631_bib42","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1093\/brain\/awac220","article-title":"The kappa free light chain index and oligoclonal bands have a similar role in the McDonald criteria","volume":"145","author":"Arrambide","year":"2022","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00631_bib43","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1177\/13524585241245306","article-title":"Radiologically isolated syndrome in the spectrum of multiple sclerosis","volume":"30","author":"Okuda","year":"2024","journal-title":"Multiple Sclerosis Journal"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00631_bib44","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000395","article-title":"Radiologically isolated syndrome in children","volume":"4","author":"Makhani","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurot.2025.e00631_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104573","article-title":"Silent findings: examination of asymptomatic demyelination in a pediatric US cohort","volume":"71","author":"Bhise","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurot.2025.e00631_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.802380","article-title":"Preventing multiple sclerosis: the pediatric perspective","volume":"13","author":"Hardy","year":"2022","journal-title":"Front Neurol"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00631_bib47","doi-asserted-by":"crossref","DOI":"10.1001\/archneurol.2009.135","article-title":"Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults","volume":"66","author":"Waubant","year":"2009","journal-title":"Arch Neurol"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00631_bib48","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1093\/brain\/awp278","article-title":"Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis","volume":"132","author":"Yeh","year":"2009","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00631_bib49","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1212\/WNL.0b013e318240799a","article-title":"Reduced head and brain size for age and disproportionately smaller thalami in child-onset MS","volume":"78","author":"Kerbrat","year":"2012","journal-title":"Neurology"},{"issue":"15","key":"10.1016\/j.neurot.2025.e00631_bib50","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000007267","article-title":"Dynamic gray matter volume changes in pediatric multiple sclerosis","volume":"92","author":"De Meo","year":"2019","journal-title":"Neurology"},{"issue":"23","key":"10.1016\/j.neurot.2025.e00631_bib51","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1212\/WNL.0000000000001045","article-title":"Onset of multiple sclerosis before adulthood leads to failure of age-expected brain growth","volume":"83","author":"Aubert-Broche","year":"2014","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00631_bib52","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1177\/1352458519829698","article-title":"Childhood multiple sclerosis is associated with reduced brain volumes at first clinical presentation and brain growth failure","volume":"25","author":"Bartels","year":"2019","journal-title":"Multiple Sclerosis Journal"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00631_bib53","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1177\/1352458515598569","article-title":"Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis","volume":"22","author":"Rocca","year":"2016","journal-title":"Multiple Sclerosis Journal"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00631_bib54","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1177\/1352458515615224","article-title":"Impaired growth of the cerebellum in pediatric-onset acquired CNS demyelinating disease","volume":"22","author":"Weier","year":"2016","journal-title":"Multiple Sclerosis Journal"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00631_bib55","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/brain\/awx041","article-title":"White matter changes in paediatric multiple sclerosis and monophasic demyelinating disorders","volume":"140","author":"Longoni","year":"2017","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00631_bib56","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1001\/jamaneurol.2023.4737","article-title":"Diagnostic performance of cortical lesions and the central vein sign in multiple sclerosis","volume":"81","author":"Cagol","year":"2024","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00631_bib57","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/13524585221142319","article-title":"Evaluating the central vein sign in paediatric-onset multiple sclerosis: a case series study","volume":"29","author":"Boccia","year":"2023","journal-title":"Multiple Sclerosis Journal"},{"issue":"14","key":"10.1016\/j.neurot.2025.e00631_bib58","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1177\/13524585221118677","article-title":"Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis","volume":"28","author":"Meaton","year":"2022","journal-title":"Multiple Sclerosis Journal"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00631_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jnnp-2022-331027","article-title":"Paramagnetic rim and core sign lesions in paediatric multiple sclerosis patients","volume":"94","author":"Margoni","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00631_bib60","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1177\/1352458519863781","article-title":"Improved performance of the 2017 McDonald criteria for diagnosis of multiple sclerosis in children in a real-life cohort","volume":"26","author":"Hacohen","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00631_bib61","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-97543-6","article-title":"Cerebrospinal fluid markers in incident pediatric-onset multiple sclerosis: a nationwide study","volume":"11","author":"McKay","year":"2021","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00631_bib62","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1212\/WNL.0b013e3181ce5db0","article-title":"Younger children with MS have a distinct CSF inflammatory profile at disease onset","volume":"74","author":"Chabas","year":"2010","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00631_bib63","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1474-4422(11)70045-X","article-title":"Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study","volume":"10","author":"Banwell","year":"2011","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00631_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088680","article-title":"Cerebrospinal fluid immunoglobulin kappa light chain in clinically isolated syndrome and multiple sclerosis","volume":"9","author":"Senel","year":"2014","journal-title":"PLoS One"},{"issue":"11\u201312","key":"10.1016\/j.neurot.2025.e00631_bib65","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1177\/13524585241274034","article-title":"The kappa free light chains index is an accurate diagnostic biomarker for paediatric multiple sclerosis","volume":"30","author":"Sarthou","year":"2024","journal-title":"Multiple Sclerosis Journal"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00631_bib66","article-title":"Glial fibrillary acidic protein and neurofilament light chain as biomarkers in pediatric multiple sclerosis","volume":"10","author":"Saucier","year":"2024","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00631_bib67","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000749","article-title":"Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis","volume":"7","author":"Reinert","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00631_bib68","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1177\/13524585221093789","article-title":"Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria","volume":"28","author":"Fadda","year":"2022","journal-title":"Multiple Sclerosis Journal"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00631_bib69","doi-asserted-by":"crossref","DOI":"10.1001\/archneurol.2010.219","article-title":"POLG1 variations presenting as multiple sclerosis","volume":"67","author":"Echaniz-Laguna","year":"2010","journal-title":"Arch Neurol"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00631_bib70","doi-asserted-by":"crossref","DOI":"10.1001\/archneurol.2010.36","article-title":"Is it ADEM, POLG, or both?","volume":"67","author":"Harris","year":"2010","journal-title":"Arch Neurol"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00631_bib71","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1177\/13524585211053565","article-title":"Isolated central nervous system familial hemophagocytic lymphohistiocytosis (fHLH) presenting as a mimic of demyelination in children","volume":"28","author":"Parida","year":"2022","journal-title":"Multiple Sclerosis Journal"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00631_bib72","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1586\/14737175.5.3.391","article-title":"Treatment of children and adolescents with multiple sclerosis","volume":"5","author":"Banwell","year":"2005","journal-title":"Expert Rev Neurother"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00631_bib73","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s11940-011-0141-x","article-title":"Current therapeutic options in pediatric multiple sclerosis","volume":"13","author":"Yeh","year":"2011","journal-title":"Curr Treat Options Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00631_bib74","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11940-014-0336-z","article-title":"Treatment of pediatric multiple sclerosis","volume":"17","author":"Narula","year":"2015","journal-title":"Curr Treat Options Neurol"},{"issue":"16_suppl l_2","key":"10.1016\/j.neurot.2025.e00631_bib75","article-title":"Treatment of pediatric multiple sclerosis and variants","volume":"68","author":"Pohl","year":"2007","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00631_bib76","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.ophtha.2022.03.021","article-title":"The pediatric optic neuritis prospective outcomes study","volume":"129","author":"Pineles","year":"2022","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00631_bib77","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/1352458513508835","article-title":"A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS","volume":"20","author":"Ramo-Tello","year":"2014","journal-title":"Multiple Sclerosis Journal"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00631_bib78","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1191\/1352458504ms978sr","article-title":"A randomized, double-blind, placebo-controlled pilot study of IV immune globulins in combination with IV methylprednisolone in the treatment of relapses in patients with MS","volume":"10","author":"Visser","year":"2004","journal-title":"Multiple Sclerosis Journal"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00631_bib79","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1212\/01.WNL.0000145798.61383.39","article-title":"IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS","volume":"63","author":"Soelberg Sorensen","year":"2004","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00631_bib80","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","article-title":"A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease","volume":"46","author":"Weinshenker","year":"1999","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00631_bib81","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/jca.21788","article-title":"scp>Double-blind<\/scp> , randomized controlled trial of therapeutic plasma exchanges vs sham exchanges in moderate-to-severe relapses of multiple sclerosis","volume":"35","author":"Brochet","year":"2020","journal-title":"J Clin Apher"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00631_bib82","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1177\/0883073814545883","article-title":"Outcomes after early administration of plasma exchange in pediatric central nervous system inflammatory demyelination","volume":"30","author":"Bigi","year":"2015","journal-title":"J Child Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00631_bib83","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10072-007-0804-2","article-title":"Treatment of early-onset multiple sclerosis with intramuscular interferon\u03b2-1a: long-term results","volume":"28","author":"Ghezzi","year":"2007","journal-title":"Neurol Sci"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00631_bib84","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1212\/01.wnl.0000198257.52512.1a","article-title":"Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis","volume":"66","author":"Banwell","year":"2006","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00631_bib85","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1191\/1352458505ms1206oa","article-title":"Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study","volume":"11","author":"Ghezzi","year":"2005","journal-title":"Multiple Sclerosis Journal"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00631_bib86","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1177\/0883073813488828","article-title":"Subcutaneous interferon beta-1a in pediatric multiple sclerosis","volume":"28","author":"Tenembaum","year":"2013","journal-title":"J Child Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00631_bib87","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1055\/s-2003-41274","article-title":"Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis","volume":"34","year":"2003","journal-title":"Neuropediatrics"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00631_bib88","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1212\/WNL.0b013e3182a2cc4a","article-title":"Glatiramer acetate\u2013induced acute hepatotoxicity in an adolescent with MS","volume":"81","author":"Makhani","year":"2013","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00631_bib89","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1056\/NEJMoa1800149","article-title":"Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis","volume":"379","author":"Chitnis","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00631_bib90","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1136\/jnnp-2019-322138","article-title":"Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIG MS study","volume":"91","author":"Arnold","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00631_bib91","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S1474-4422(21)00364-1","article-title":"Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial","volume":"20","author":"Chitnis","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2025.e00631_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.606418","article-title":"Delayed-release dimethyl fumarate safety and efficacy in pediatric patients with relapsing-remitting multiple sclerosis","volume":"11","author":"Alroughani","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurot.2025.e00631_bib93","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.pediatrneurol.2018.03.007","article-title":"Safety and efficacy of delayed-release dimethyl fumarate in pediatric patients with relapsing multiple sclerosis (FOCUS)","volume":"83","author":"Alroughani","year":"2018","journal-title":"Pediatr Neurol"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00631_bib94","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.30439","article-title":"Effect of dimethyl fumarate vs interferon \u03b2-1a in patients with pediatric-onset multiple sclerosis","volume":"5","author":"Vermersch","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00631_bib95","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12883-015-0433-y","article-title":"Natalizumab in the pediatric MS population: results of the Italian registry","volume":"15","author":"Ghezzi","year":"2015","journal-title":"BMC Neurol"},{"key":"10.1016\/j.neurot.2025.e00631_bib96","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.pediatrneurol.2017.01.017","article-title":"The use of natalizumab in pediatric patients with active relapsing multiple sclerosis: a prospective study","volume":"70","author":"Alroughani","year":"2017","journal-title":"Pediatr Neurol"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00631_bib97","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jamaneurol.2013.923","article-title":"Natalizumab therapy for highly active pediatric multiple sclerosis","volume":"70","author":"Kornek","year":"2013","journal-title":"JAMA Neurol"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00631_bib98","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1212\/WNL.0b013e3181f11daf","article-title":"Safety and efficacy of natalizumab in children with multiple sclerosis","volume":"75","author":"Ghezzi","year":"2010","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00631_bib99","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000208114","article-title":"Comparative effectiveness of natalizumab, fingolimod, and injectable therapies in pediatric-onset multiple sclerosis","volume":"102","author":"Spelman","year":"2024","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00631_bib100","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00631_bib101","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing\u2013remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00631_bib102","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00631_bib103","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00631_bib104","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJMoa2201904","article-title":"Ublituximab versus teriflunomide in relapsing multiple sclerosis","volume":"387","author":"Steinman","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00631_bib105","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s00415-015-7979-x","article-title":"Rituximab in paediatric onset multiple sclerosis: a case series","volume":"263","author":"Salzer","year":"2016","journal-title":"J Neurol"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00631_bib106","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16228","article-title":"Rituximab treatment in <scp>pediatric-onset<\/scp> multiple sclerosis","volume":"31","author":"Breu","year":"2024","journal-title":"Eur J Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00631_bib107","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00415-024-12879-z","article-title":"Ocrelizumab dose selection for treatment of pediatric relapsing-remitting multiple sclerosis: results of the OPERETTA I study","volume":"272","author":"Mar","year":"2025","journal-title":"J Neurol"},{"key":"10.1016\/j.neurot.2025.e00631_bib108","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pediatrneurol.2023.04.020","article-title":"Demographic features and clinical course of patients with pediatric-onset multiple sclerosis on newer disease-modifying treatments","volume":"145","author":"Malani Shukla","year":"2023","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.neurot.2025.e00631_bib109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpn.2023.01.011","article-title":"Ocrelizumab in pediatric multiple sclerosis","volume":"43","author":"Bibino\u011flu Amirov","year":"2023","journal-title":"Eur J Paediatr Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00631_bib110","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.36321","article-title":"Association of rituximab use with adverse events in children, adolescents, and young adults","volume":"4","author":"McAtee","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00631_bib111","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1212\/WNL.0000000000000570","article-title":"Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease","volume":"83","author":"Dale","year":"2014","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00631_bib112","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/13524585231223069","article-title":"Control of disease activity with large extended-interval dosing of rituximab\/ocrelizumab in highly active pediatric multiple sclerosis","volume":"30","author":"Venet","year":"2024","journal-title":"Multiple Sclerosis Journal"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00631_bib113","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00631_bib114","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S2352-4642(24)00047-6","article-title":"Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries","volume":"8","author":"Sharmin","year":"2024","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.neurot.2025.e00631_bib115","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231194823","article-title":"Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study","volume":"16","author":"Coles","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00631_bib116","article-title":"Short-term outcomes of pediatric multiple sclerosis patients treated with alemtuzumab at a Canadian University multiple sclerosis clinic","volume":"6","author":"Jure Hunt","year":"2020","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"10.1016\/j.neurot.2025.e00631_bib117","first-page":"16","article-title":"Alemtuzumab following natalizumab is more effective in adult-onset than paediatric-onset multiple sclerosis","author":"Puthenparampil","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00631_bib118","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/13524585241295554","article-title":"Safety, efficacy, and tolerability of alemtuzumab in pediatric patients with active relapsing-remitting multiple sclerosis: the LemKids study","volume":"31","author":"Chitnis","year":"2025","journal-title":"Multiple Sclerosis Journal"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00631_bib119","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1017\/cjn.2020.66","article-title":"Treatment optimization in multiple sclerosis: Canadian MS working group recommendations","volume":"47","author":"Freedman","year":"2020","journal-title":"Can J Neurol Sci\/J Can Sci Neurol"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00631_bib120","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11940-019-0592-z","article-title":"Newer treatment approaches in pediatric-onset multiple sclerosis","volume":"21","author":"Macaron","year":"2019","journal-title":"Curr Treat Options Neurol"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00631_bib121","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3390\/children6060073","article-title":"Long-term treatment strategies of pediatric multiple sclerosis, including the use of disease modifying therapies","volume":"6","author":"Rensel","year":"2019","journal-title":"Children"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00631_bib122","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/ene.13692","article-title":"Early versus later treatment start in multiple sclerosis: a register-based cohort study","volume":"25","author":"Chalmer","year":"2018","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurot.2025.e00631_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.101956","article-title":"Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: a prospective Danish cohort study","volume":"40","author":"Kopp","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00631_bib124","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1177\/1352458519846100","article-title":"Predictors of treatment outcome in patients with paediatric onset multiple sclerosis","volume":"26","author":"Kopp","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00631_bib125","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1001\/jamaneurol.2021.1008","article-title":"Risk of persistent disability in patients with pediatric-onset multiple sclerosis","volume":"78","author":"Baroncini","year":"2021","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00631_bib126","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/jamaneurol.2023.4455","article-title":"Multiple sclerosis progression and relapse activity in children","volume":"81","author":"Iaffaldano","year":"2024","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00631_bib127","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ana.25737","article-title":"Real-world effectiveness of initial disease-modifying therapies in pediatric <scp>Multiple sclerosis<\/scp&gt","volume":"88","author":"Krysko","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2025.e00631_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104942","article-title":"Early use of high efficacy therapies in pediatric forms of relapsing-remitting multiple sclerosis: a real-life observational study","volume":"79","author":"Moreau","year":"2023","journal-title":"Mult Scler Relat Disord"},{"issue":"22","key":"10.1016\/j.neurot.2025.e00631_bib129","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000009522","article-title":"Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis","volume":"94","author":"Landmeyer","year":"2020","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00631_bib130","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ejpn.2019.08.007","article-title":"Early effective treatment may protect from cognitive decline in paediatric multiple sclerosis","volume":"23","author":"Johnen","year":"2019","journal-title":"Eur J Paediatr Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00631_bib131","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1001\/jamaneurol.2013.5486","article-title":"Disease activity free status","volume":"71","author":"Bevan","year":"2014","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00631_bib132","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1756285614560733","article-title":"Towards the implementation of \u2018no evidence of disease activity\u2019 in multiple sclerosis treatment: the multiple sclerosis decision model","volume":"8","author":"Stangel","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00631_bib133","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.msard.2012.12.001","article-title":"Editors' welcome and a working definition for a multiple sclerosis cure","volume":"2","author":"Banwell","year":"2013","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00631_bib134","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","article-title":"Evaluation of No evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort","volume":"72","author":"Rotstein","year":"2015","journal-title":"JAMA Neurol"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00631_bib135","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1177\/1352458515616701","article-title":"Inclusion of brain volume loss in a revised measure of \u2018no evidence of disease activity\u2019 (NEDA-4) in relapsing\u2013remitting multiple sclerosis","volume":"22","author":"Kappos","year":"2016","journal-title":"Multiple Sclerosis Journal"},{"issue":"13","key":"10.1016\/j.neurot.2025.e00631_bib136","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1177\/1352458521998039","article-title":"Plasma neurofilament light chain levels are predictors of disease activity in multiple sclerosis as measured by four-domain NEDA status, including brain volume loss","volume":"27","author":"Szilasiov\u00e1","year":"2021","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1016\/j.neurot.2025.e00631_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116827","article-title":"Five- and seven-year prognostic value of new effectiveness measures (NEDA, MEDA and six-month delayed NEDA) in relapsing-remitting multiple sclerosis","volume":"414","author":"Tsantes","year":"2020","journal-title":"J Neurol Sci"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00631_bib138","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1136\/jnnp-2019-322348","article-title":"Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis","volume":"91","author":"Prosperini","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00631_bib139","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2018.18743","article-title":"Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis","volume":"321","author":"Burt","year":"2019","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00631_bib140","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1136\/jnnp-2018-319446","article-title":"Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis","volume":"90","author":"Moore","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00631_bib141","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jamaneurol.2014.3780","article-title":"High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS)","volume":"72","author":"Nash","year":"2015","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00631_bib142","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000565","article-title":"Pilot study of a ketogenic diet in relapsing-remitting MS","volume":"6","author":"Brenton","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00631_bib143","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1136\/jnnp-2022-329074","article-title":"Phase II study of ketogenic diets in relapsing multiple sclerosis: safety, tolerability and potential clinical benefits","volume":"93","author":"Brenton","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00631_bib144","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1136\/jnnp-2017-315936","article-title":"Contribution of dietary intake to relapse rate in early paediatric multiple sclerosis","volume":"89","author":"Azary","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00631_bib145","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jpsychores.2014.03.014","article-title":"Exercise training improves depressive symptoms in people with multiple sclerosis: results of a meta-analysis","volume":"76","author":"Ensari","year":"2014","journal-title":"J Psychosom Res"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00631_bib146","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/ene.12576","article-title":"The effect of exercise on depressive symptoms in multiple sclerosis based on a meta-analysis and critical review of the literature","volume":"22","author":"Dalgas","year":"2015","journal-title":"Eur J Neurol"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00631_bib147","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.apmr.2015.02.011","article-title":"Exercise as a therapy for improvement of walking ability in adults with multiple sclerosis: a meta-analysis","volume":"96","author":"Pearson","year":"2015","journal-title":"Arch Phys Med Rehabil"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00631_bib148","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/1545968308320641","article-title":"Effect of exercise training on walking mobility in multiple sclerosis: a meta-analysis","volume":"23","author":"Snook","year":"2009","journal-title":"Neurorehabilitation Neural Repair"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00631_bib149","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/1352458507080464","article-title":"Effect of exercise training on quality of life in multiple sclerosis: a meta-analysis","volume":"14","author":"Motl","year":"2008","journal-title":"Multiple Sclerosis Journal"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00631_bib150","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1177\/1352458521996002","article-title":"Which exercise and behavioural interventions show most promise for treating fatigue in multiple sclerosis? A network meta-analysis","volume":"27","author":"Harrison","year":"2021","journal-title":"Multiple Sclerosis Journal"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00631_bib151","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1177\/1352458520974360","article-title":"Youth with multiple sclerosis have low levels of fitness","volume":"27","author":"Stephens","year":"2021","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1016\/j.neurot.2025.e00631_bib152","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jpeds.2016.08.104","article-title":"Physical activity and its correlates in youth with multiple sclerosis","volume":"179","author":"Grover","year":"2016","journal-title":"J Pediatr"},{"issue":"19","key":"10.1016\/j.neurot.2025.e00631_bib153","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1212\/WNL.0000000000001939","article-title":"Lower physical activity is associated with higher disease burden in pediatric multiple sclerosis","volume":"85","author":"Grover","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00631_bib154","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jpeds.2019.01.040","article-title":"Benefits of physical activity for depression and fatigue in multiple sclerosis: a longitudinal analysis","volume":"209","author":"Stephens","year":"2019","journal-title":"J Pediatr"},{"key":"10.1016\/j.neurot.2025.e00631_bib155","first-page":"1","article-title":"Physical activity and functional limitations in pediatric multiple sclerosis: are fatigue and depression confounding variables?","author":"Sikes","year":"2023","journal-title":"J Pediatr Rehabil Med"},{"key":"10.1016\/j.neurot.2025.e00631_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103467","article-title":"Feasibility of a theory-informed mobile app for changing physical activity in youth with multiple sclerosis","volume":"58","author":"Stephens","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00631_bib157","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/dmcn.12964","article-title":"Understanding fatigue in paediatric multiple sclerosis: a systematic review of clinical and psychosocial factors","volume":"58","author":"Carroll","year":"2016","journal-title":"Dev Med Child Neurol"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00631_bib158","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1212\/WNL.45.11.1956","article-title":"Fatigue therapy in multiple sclerosis","volume":"45","author":"Krupp","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00631_bib159","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.msard.2017.10.011","article-title":"Meta-analysis of the efficacy of modafinil versus placebo in the treatment of multiple sclerosis fatigue","volume":"19","author":"Shangyan","year":"2018","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00631_bib160","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1474-4422(20)30354-9","article-title":"Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial","volume":"20","author":"Nourbakhsh","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2025.e00631_bib161","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1235945","article-title":"Interim guidelines for the assessment and treatment of pain in children with multiple sclerosis","volume":"17","author":"Stratton","year":"2023","journal-title":"Front Neurosci"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925001096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925001096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:11:47Z","timestamp":1762560707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747925001096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":161,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1878747925001096"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00631","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pediatric multiple sclerosis: Improving outcome through high-efficacy therapies","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00631","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00631"}}